TMCnet News
Metabolomics: Technologies and Global MarketsNEW YORK, Feb. 18, 2019 /PRNewswire/ -- Report Scope: Drivers and challenges in each subsegment of this industry are described in detail, including forecasts for the next five years. This report also analyzes key marketed products, recent product launches and the regulatory landscape across different demographics.An overview is provided of the demographics of key regions, including North America, Europe, Asia-Pacific, Latin America and the Middle East. Potential growth at regional and country levels is also covered. The strategies of global companies engaged in the metabolomic space and profiles of top companies are covered. Clinical biomarkers used in metabolomic research are not included in this report. Report Includes: - 86 data tables and 16 additional tables - Brief overview and industry analysis of the global markets for metabolomics technologies - Analyses of global market trends with data from 2016 to 2018, and projections of compound annual growth rates (CAGRs) through 2023 - Assessment of the key marketed products and recent product launches, regulatory landscape across different demographics covering North America, Europe, Asia-Pacific, Latin America and Middle East - Examination of the main structure of the metabolomics market by segments, key application areas, and market participants - Market dynamics and estimated data regarding metabolomics by technological platforms (analytical instruments), detection techniques, separation techniques, assays, disease indication types, applications and geographical regions - Identification of leading biotechnology companies poised to introduce products during the forecast period, and their impact on the face of the competitive environment - Detailed profiles of the leading companies in the metabolomics market, including LECO Corp., Metabolon Inc., Shimadzu Corp., Thermo Fisher Scientific Inc., and Waters Corp. Summary The global metabolomics market is expected to reach about REDACTED by 2023, increasing at a compound annual growth rate (CAGR) of REDACTED from 2018 through 2023.The major drivers of market growth are increasing investment in metabolomic research through public and private funding, increasing applications of metabolomics in personalized medicine, increasing R&D funding for pharmaceutical and biotech companies and increasing technological advancements in this market arena. However, the shortage of qualified technicians, high cost of tools and instruments, and the complexity associated with metabolomic data examination and processing pose threats to market growth. Based on products, the separation technique market accounted for REDACTED of the global metabolomics market in 2017.However, the bioinformatic market is expected grow at the highest CAGR of REDACTED during the forecast period of 2018 to 2023. High growth in this application segment is mainly attributed to the increasing usage of different bioinformatic platforms in various metabolomic applications such as drug discovery and development and the benefit of smooth technological workflow with the precise,reliable and transparent data processing benefits gained from it. The geographic analysis reveals that North America dominated the market in 2017, accounting for the largest share, REDACTED, of the global metabolomics market.This market is projected to reach REDACTED billion by 2023 from REDACTED in 2018, at a CAGR of REDACTED during the forecast period. The dominance of North America is justified by the presence of a wide pool of market players offering their products in the metabolomics market. These companies include Agilent Technologies Inc., Bio-Rad Laboratories, BrukerCorp., Danaher Corp., Human Metabolome Technologies Inc., LECO Corp., Metabolon Inc., Shimadzu Corp., Thermo Fisher Scientific Inc. and Waters Corp., among others. In addition, easy availability of technologically advanced products and significant investments in metabolomic-based research in drug discovery studies, personalized medicine and cancer therapeutics will also drive the North American market during the forecast period.For instance, as of 2017, the United States' Congress has increased its budget for medical research by allocating REDACTED to medical research at the National Institutes of Health (NIH). Also, Congress has increased cancer research funding to about REDACTED. However, the market for metabolomics in the Asia-Pacific region is expected to grow at the highest CAGR of REDACTED during the forecast period. Asia-Pacific's high growth rate is attributed to unmet healthcare needs, high prevalence of cancer, high investments in metabolomic-based research, improving pharmaceutical research infrastructure and growing R&D funding for cancer drug discovery and personalized medicine opportunities. Read the full report: https://www.reportlinker.com/p01105927 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
SOURCE Reportlinker 
|
View original content: